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Abstract
Introduction: Cyclophosphamide-based adjuvant chemotherapy is a mainstay of treatment for women with node-
positive breast cancer, but is not universally effective in preventing recurrence. Pharmacogenetic variability in drug 
metabolism is one possible mechanism of treatment failure. We hypothesize that functional single nucleotide 
polymorphisms (SNPs) in drug metabolizing enzymes (DMEs) that activate (CYPs) or metabolize (GSTs) 
cyclophosphamide account for some of the observed variability in disease outcomes.
Methods: We performed a retrospective cohort study of 350 women enrolled in a multicenter, randomized, adjuvant 
breast cancer chemotherapy trial (ECOG-2190/INT-0121). Subjects in this trial received standard-dose 
cyclophosphamide, doxorubicin and fluorouracil (CAF), followed by either observation or high-dose 
cyclophosphamide and thiotepa with stem cell rescue. We used bone marrow stem cell-derived genomic DNA from 
archival specimens to genotype CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5, GSTM1, GSTT1, and GSTP1. Cox regression 
models were computed to determine associations between genotypes (individually or in combination) and disease-
free survival (DFS) or overall survival (OS), adjusting for confounding clinical variables.
Results: In the full multivariable analysis, women with at least one CYP3A4 *1B variant allele had significantly worse 
DFS than those who were wild-type *1A/*1A (multivariate hazard ratio 2.79; 95% CI 1.52, 5.14). CYP2D6 genotype did 
not impact this association among patients with estrogen receptor (ER) -positive tumors scheduled to receive 
tamoxifen.
Conclusions: These data support the hypothesis that genetic variability in cyclophosphamide metabolism 
independently impacts outcome from adjuvant chemotherapy for breast cancer.
Introduction
Women with node-positive breast cancer typically
receive cyclophosphamide-based adjuvant chemother-
apy, but a significant proportion of these women relapse
and ultimately die of their disease. A growing body of lit-
erature suggests that individual variability in drug metab-
olism impacts pharmacodynamics and subsequent
efficacy [1]. Functional single nucleotide polymorphisms
(SNPs) in drug metabolizing enzymes (DMEs) are a
major determinant of this variability [2].
Cyclophosphamide is administered as an inactive prod-
rug that must undergo activation through phase I metab-
olism by cytochrome P450 (CYP) enzymes 2B6, 3A4,
3A5, and 2C9 and phase II inactivation primarily through
conjugation with a thiol or sulfate via glutathione S-trans-
ferases (GSTs) alpha, mu, theta or pi as shown in Figure 1.
The active metabolite, 4-hydroxy-cyclophosphamide dif-
fuses into cancer cells [3] and is responsible for cyclo-
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phosphamide's alkylating ability [4,5]. Functional SNPs in
these enzymes impact enzyme activity and metabolite
levels. Several small prior studies, including our own,
support the hypothesis that functional SNPs in these
phase I and phase II enzymes impact clinical outcome in
breast cancer [6-8].
To further evaluate this hypothesis, we examined
whether cyclophosphamide-DME SNPs were indepen-
dently associated with disease-free or overall survival
(DFS, OS) in a cohort of women enrolled in a multicenter,
randomized, adjuvant breast cancer chemotherapy trial.
Materials and methods
We performed a retrospective cohort study utilizing
genomic DNA derived from hematologic circulating or
bone-marrow-derived stem cells and clinical data from
breast cancer patients enrolled on Intergroup Trial 0121
(E2190/SWOG9061/CALGB 9496), a multicenter trial of
h i g h  d o s e  v s .  s t a n d a r d  d o s e  a d j u v a n t  c h e m o t h e r a p y .
Patients were included in the current study if they were
enrolled in INT-0121, informed consent was confirmed,
and archival peripheral blood or bone marrow stem cells
were available for genomic DNA extraction and subse-
Figure 1 Cyclophosphamide metabolism.
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quent genotyping. This study is in compliance with the
Helsinki Declaration and was performed with the
approval of the University of Pennsylvania Institutional
Review Board and the Eastern Cooperative Oncology
Group (ECOG) Executive Committee.
Results of E2190/INT-0121 trial have been published
previously [9]. Briefly, 540 patients with ≥10 positive
lymph nodes received conventional adjuvant therapy
with four cycles of cyclophosphamide (C; 100 mg/m2,
orally, Days 1 to 14), doxorubicin (A; 30 mg/m2, intrave-
nously, Days 1, 8), and fluorouracil (F; 500 mg/m2, intra-
venously, Days 1, 8) followed by randomization to either
observation or receipt of high-dose chemotherapy (HDC:
cyclophosphamide (6 gm/m2) and thiotepa (800 mg/m2)
over a four-day period) with hematopoietic stem cell
reinfusion. Adjuvant tamoxifen was recommended for
p a t i e n t s  w i t h  e s t r o g e n  r e c e p t o r  ( E R )  p o s i t i v e  t u m o r s ,
although receipt of this medication was not tracked in the
study database.
The protocol specified hematopoietic stem cell collec-
tion at the completion of standard CAF for all patients on
the study. Specimens not utilized for autologous reinfu-
sion were stored at -80 C at the ECOG Pathology Core
Facility (Chicago, IL, USA). The original INT-0121 con-
sent form included language specifying that residual bio-
logical specimens would be used for future breast cancer
research. The ECOG Statistical Center (Boston, MA,
USA) performed additional follow-up and de-linked
patient identifiers from the clinical data used in this anal-
ysis. The primary endpoint for this study was DFS,
defined as time from randomization to earliest recur-
rence, new breast cancer, or death. The secondary end-
point was overall survival, defined as time from
randomization to death [9]. All survival times were cen-
sored at time of last contact or on 1 August 2005 if sub-
jects were alive and disease-free at that time.
We selected 15 SNPs (CYP2B6*4, CYP2B6*5,
CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2C9*2,
CYP2C9*3, CYP3A4*1B, CYP3A5*3, CYP3A5*6,
CYP2D6*4, GSTM1, GSTT1, GSTP1*B, GSTP1*C) in
eight genes for inclusion by first identifying cyclophosph-
amide-metabolizing enzyme polymorphisms that were
associated with functional effects on enzyme expression,
levels or activity, then excluding those in which the
expected prevalence of the combination of alleles for a
particular gene was ≤ 10% of the general population, since
these constituted a minute fraction of cyclophosphamide
metabolism and significant effects for these SNPs were
unlikely to be detectable with the sample size available.
All variants were hypothesized to result in decreased
enzyme function [10]. Of note, genotyping for CYP2D6*4
was included to account for any possible differential
effect of variable tamoxifen metabolism on outcome
among patients whose tumors were estrogen-receptor
positive.
The ECOG Pathology Core Facility at Northwestern
University extracted DNA from hematologic stem cells
with the EZ1 system (Qiagen, Inc, Hilden, NW, Ger-
many). Genotyping was performed at the University of
Pennsylvania. GSTM1 and GSTT1 homozygous null
mutations were detected using a method previously
described, using a 4% metaphor agarose gel [11,12]. The
remainder of genotyping was determined by PyroSe-
quencing (CYP2C9*3, CYP3A4*1B, CYP3A5*3,
CYP3A5*6, GSTP1*B, GSTP1*C) (Biotage, Charlottes-
ville, VA, USA, Applied Biosystems, Foster City, CA,
USA)) and Taqman Real-Time PCR assays on the MJ
Research Chromo4 (Bio-Rad) platform (CYP2B6*4,
CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*9,
CYP2C9*2, CYP2D6*4). The technician performing gen-
otype assays was blinded to all clinical and outcome data.
Polymorphisms were examined individually and in gen-
otype groups defined based on our prior work [6]. With
regard to CYP2B6, assignment of genotype was carried
out as follows: carriers of the A785G mutation alone were
designated CYP2B6*4; carriers of the C1459T mutation
alone were designated CYP2B6*5; carriers of the combi-
nation of A785G and G516T were designated CYP2B6*6;
carriers of the combination of A785G, G516T, and
C1459T were designated CYP2B6*7; and carriers of the
G516T mutation alone were designated CYP2B6*9 (data
not shown). Because of the similarly anticipated direc-
tions of effect and the lack of power to perform compari-
sons with each polymorphism, dichotomous CYP2B6,
CYP2C9, and GSTP1 variables were created based on
genotype, where groupings consisted of all wild-type ver-
sus carriers of any variant.
To validate our pilot work assessing combined effects of
variants in both activating (CYP) and metabolizing (GST)
enzymes, we also classified subjects into three groups
(favorable, intermediate and unfavorable) based on their
CYP3A4*1B, CYP3A5*3, GSTM1 and GSTT1 genotypes
[6]. The favorable group was comprised of subjects with
no variant in either CYP3A4 or CYP3A5 and null at both
GSTM1 and GSTT1. The unfavorable group was com-
prised of subjects who were variant in either CYP3A4 or
CYP3A5 and non-null at both GSTM1 and GSTT1. The
intermediate group comprised all other CYP/GST combi-
nations. The groups were hypothesized to have varying
serum concentrations of active cyclophosphamide
metabolites based on known functional significance of
the genetic variants.
STATA (Release 9, Stata Corporation, College Station,
TX, USA) and R (Version 2.3.1, R Foundation for Statisti-
cal Computing, Vienna, Austria) software were used for
statistical analysis. Pearson's chi-squared or exact testsGor et al. Breast Cancer Research 2010, 12:R26
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for small samples were used to compare proportions.
Survival curves were generated using the Kaplan-Meier
method [13] and were compared using the log-rank test.
Cox regression models were computed to determine the
hazard ratio associated with each genotype, genotype
group or clinical variable and both DFS and OS. Indicator
variables for categorical variables included a category for
missing data. The Grambsch-Therneau test was used to
test the proportional hazards assumption [14]. Multivari-
able Cox models for DFS and OS were developed by
including all genotype and clinical variables. All tests of
significance were two-sided, with alpha = 0.05.
Results
A total of 433 peripheral blood or bone marrow stem cell
specimens for genomic DNA from 540 patients originally
enrolled in INT-0121 were identified for study from the
ECOG Pathology Core Facility. Fifty-two samples could
not be linked to clinical data and follow-up; 31 samples
were duplicates. Thus, a final study cohort of 350 subjects
(65% of parent trial) was available for this analysis.
Clinical characteristics of all 540 INT-0121 patients as
well as those genotyped (n = 350) appear in Table 1. Gen-
otyped subjects were more likely to be enrolled in the
CAF + HDC arm compared to the non-genotyped group
(57% v. 38%, P < 0.001), likely due to the fact that some
patients randomized to the observation arm did not have
bone marrow or stem cells collected post-adjuvant ther-
a p y ,  r e s u l t i n g  i n  m o r e  bo n e  m a rr o w / s t e m  c e l l  s a m p l es
collected for those patients randomized to the transplant
arm than to the observation arm. Overall, women in the
genotyped cohort had significantly shorter DFS than
women in the study overall and those not genotyped, but
did not differ with respect to OS.
Of the 350 subjects in this study, 152 patients were in
the standard therapy (CAF) arm and 198 in the high-dose
therapy (CAF + HDC) arm. No significant differences in
clinical characteristics between the two groups were
found (data not shown). The median follow-up for the
136 patients without DFS events by the cutoff date was
9.8 years, with a range of 3.6 to 13.4 years; only 32 (9%)
had DFS censored at dates earlier than 8/1/05, and only
12 had DFS censored at dates earlier than 8/1/04. The
standard arm had median follow-up of 9.60 years with a
recurrence rate (RR) of 63%, while the high-dose therapy
arm had a slightly longer median follow-up of 9.9 years
with a RR of 48%, though 10-year DFS and OS were not
significantly different between the two groups (P = 0.08
and P = 0.62, respectively). Because there were no signifi-
cant differences in baseline characteristics or survival
between the CAF and CAF+HDC arms in the genotyped
cohort, we combined the two groups for survival end-
points and adjusted for treatment arm in multivariable
analyses.
Table 1: Study population and comparison to full trial
Characteristic Genotyped Study
Cohort N = 350
Full E2190/INT-0121
Cohort N = 540
P-value1
Median (IQR)2 Median (IQR)2
Age 45 (39 to 50) 44 (38 to 50) 0.35
Axillary LN positive 14 (11 to 19) 14 (11 to 18) 0.13
Tumor size, cm 3.5 (2.1 to 5.0) 3.5 (2.1 to 5.0) 0.90
Median follow-up years 9.8 (8.3 to 11.2) 9.7 (8.1 to 11.4) 0.57
Percent (95% CI) Percent (95% CI)
Postmenopausal 31 (26 to 35) 29 (25 to 33) 0.22
Race - Caucasian 90 (87 to 93) 89 (86 to 91) 0.58
ER + 59 (54 to 64) 60 (56 to 64) 0.70
PR + 56 (51 to 61) 59 (54 to 63) 0.12
Lumpectomy 17 (13 to 20) 19 (15 to 22) 0.10
Treatment arm CAF+HDC 57 (51 to 62) 50 (47 to 54) <0.001
10-year DFS (%) 39 (34 to 44) 43 (38 to 47) 0.02
10-year OS (%) 45 (40 to 51) 48 (44 to 52) 0.09
1Pearson's chi-square test
2Interquartile range
CAF: cyclophosphamide, doxorubicin fluorouracil; CI: confidence interval; DFS: disease free survival; ER: estrogen receptor; HDC: high dose 
chemotherapy; LN: lymph nodes; OS: overall survival; PR: progesterone receptor.Gor et al. Breast Cancer Research 2010, 12:R26
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Table 2: Genotype frequencies
SNP Variants Genotypes White  # (%) 
(n = 314)
Black # (%) 
(n = 19)
Other # (%)
(n = 17)
P-value1
CYP2B6 All WT 516 G/G 114 (36) 4 (21) 4 (23) 0.14
(rs2279343, 785   A/A
rs3211371, 1459 C/C
rs3745274) Any Var Any Var 189 (60) 15 (79) 11 (65)
Missing 11 (4) 0 (0) 2 (12)
CYP2C9 All Wild- 430 C/C 176 (56) 17 (89) 9 (53) 0.06
(rs1799853, type 1075 A/A
rs1057910) Any Var Any Var 107 (34) 2 (11) 7 (41)
Missing 31 (10) 0 (0) 1 (6)
CYP2D6*4 *1/*1 A/A 19 (6) 0 (0) 0 (0) 0.81
(rs3892097) *1/*4 G/A 86 (27) 4 (21) 4 (27)
*4/*4 G/G 198 (63) 15 (79) 11 (63)
Missing 11 (4) 0 (0)
CYP3A4*1B *1A/*1A A/A 281 (89) 5 (26) 13 (76) <0.001
(rs2740574) *1A/*1B G/A 20 (6) 7 (37) 2 (12)
*1B/*1B G/G 3 (1) 7 (37) 0 (0)
Missing 10 (3) 0 (0) 2 (12)
CYP3A5*3 *1/*1 A/A 4 (1) 9 (47) 0 (0) <0.001
(rs776746) *1/*3 G/A 39 (12) 8 (42) 5 (29)
*3/*3 G/G 260 (83) 1 (5) 11 (65)
Missing 11 (4) 1 (5) 1 (6)
CYP3A5*6 *1/*1 G/G 307 (98) 15 (79) 16 (94) <0.001
(rs10264272) *1/*6 A/G 1 (<1) 4 (21) 0 (0)
*6/*6 A/A 0 (0) 0 (0) 0 (0)
Missing 6 (2) 0 (0) 1 (6)
GSTM1 Non-null 135 (43) 11 (58) 9 (53) 0.09
Null 171 (54) 7 (37) 6 (35)
Missing 8 (3) 1 (5) 2 (12)
GSTT1 Non-null 254 (81) 10 (53) 13 (76) 0.02
Null 51 (16) 8 (42) 2 (12)
GSTT1 Missing 9 (3) 1 (5) 2 (12)
GSTP1 All WT Ex 5-24A/A 146 (47) 6 (32) 7 (41) 0.11
(rs1695, rs1138272) Ex 6+5 C/C
Any Var Any Variant 160 (51) 13 (68) 8 (47)
Missing 8 (3) 0 (0) 2 (1)
Combined CYP-GST genotype Favorable 0 (0) 0 (0) 0 (0) 0.06
groups Intermediate 186 (60) 15 (79) 6 (35)
Unfavorable 102 (32) 3 (16) 8 (47)
Missing 26 (8) 1 (5) 3 (18)
1 Exact Pearson's or Chi-square test
SNP: single nucleotide polymorphismGor et al. Breast Cancer Research 2010, 12:R26
http://breast-cancer-research.com/content/12/3/R26
Page 6 of 10
Genotypic frequencies by race are shown in Table 2.
These are consistent with reported frequencies in the
NCI SNP500 database [15]. Because of the paucity of
observations for non-white, non-black racial/ethnic
groups, we grouped race categories into White, Black,
and  Other.  A single missing observation was grouped
with the Other  category. Significant racial differences
were seen in CYP2B6, CYP2C9, CYP3A4, CYP3A5, and
GSTT1 SNP frequencies; we therefore adjusted for race
in the multivariable analysis.
Table 3 shows unadjusted hazard ratios for DFS and
OS. CYP3A4*1B variants were associated with decreased
DFS compared to *1B wild-type, while GSTM1 null geno-
types were associated with improved DFS and OS com-
pared to those with non-null genotype. The prespecified
unfavorable CYP/GST genotype group had decreased
DFS and OS when compared to the intermediate and
favorable groups, though this was not statistically signifi-
cant.
Adjusted hazard ratios (HRs) for DFS and OS were
determined for the full multivariable models that
included the collapsed dichotomous CYP2B6, CYP2C9,
and GSTP1 variables, as well as CYP3A4, CYP3A5 (*3
and *6), GSTM1, and GSTT1. This model also included
age, number of positive lymph nodes, tumor size, PR sta-
tus, race, and treatment arm. Applying the Grambsch-
Therneau test for proportional hazards to the fully-
adjusted DFS and OS models, estrogen receptor status
showed significant evidence of non-proportionality for
both outcomes (DFS P  = 0.003; OS P  < 0.001). Thus,
stratified multivariable Cox models were computed using
ER status as a stratification variable to allow for differing
underlying hazards in the two estrogen receptor status
groups. In the full model for DFS, women heterozygous
for the CYP3A4 *1B variant had significantly worse DFS
than those who were wild-type (*1A/*1A; hazard ratio
[HR] 2.79; 95% CI 1.52, 5.14) (Table 4). Women with the
null GSTM1 genotype did not have significantly
improved DFS or OS in the full models. Of the clinical
variables, the number of lymph nodes (HR 1.02, 95% CI
1.00, 1.04) and the treatment arm (CAF+HDC vs. CAF
HR 0.66, 95% CI 0.48, 0.91) remained significantly associ-
ated with DFS (Table 4).
Because the treatment arm was of significance in the
full DFS model, we performed stratified analyses of DFS
and OS by treatment arm for each genotype to look for
interactions. Treatment arm appeared to modify the rela-
tionship between genotype and outcome only for GSTT1
(Figure 2). While a significant difference in DFS by this
genotype was seen in the standard therapy (CAF) arm
(Adjusted DFS HR 1.95, P = 0.053), it was not seen in the
high-dose arm (Adjusted DFS HR 0.91, P = 0.72). Nota-
bly, there have been no relapses or deaths in the high-
dose arm beyond the time of median follow-up, whereas
this appears not to be the case for the low-dose arm, in
which failures have continued to occur with longer fol-
low-up. The interaction term P-values for DFS was P =
0.04, revealing that for DFS, there was a significant inter-
action between GSTT1 genotype and dose of cyclophos-
phamide. This interaction was not seen in the analysis of
overall survival.
Discussion
We found that women who received cyclophosphamide-
based adjuvant chemotherapy for breast cancer and had
the CYP3A4 *1B*/*1A genotype had significantly worse
DFS than those who were CYP3A4 *1A/*1A wild-type
(HR 2.44, 95% CI 1.52, 5.14). These findings support our
hypothesis that reduced phase I enzyme activity (via the
CYP3A4*1B polymorphism) leads to a poorer outcome
after cyclophosphamide-based adjuvant chemotherapy,
presumably as a result of slower activation of cyclophos-
phamide to HCY. Women with the GST-T1 null genotype
had significantly better DFS and OS than those without
the variant, though this effect was limited to patients on
the standard-dose therapy arm (adjusted DFS HR 1.95, P
= 0.053).
These data confirm, in a much larger, multicenter
patient population in which half of all patients received
standard doses of chemotherapy, earlier published data
by our group and others examining the effects of cyclo-
phosphamide DME SNPs on breast cancer outcomes. We
previously published a single institution study of SNPs in
CYP3A4, 3A5*3, 3A5*6, GSTM1 and GSTT1 in which a
model utilizing a-priori-defined genotype combinations
showed that patients with an unfavorable  SNP profile
(consisting of either a CYP3A4*1B variant or a CYP3A5*3
variant and wild-type GST T1 and M1) had a significantly
increased odds of death compared to those with the
favorable genotype (HR 4.6, P  = 0.045) [6]. While we
could not replicate our original analysis using a compos-
ite genotype group in this study due to the lack of patients
with the favorable SNP profile, we did see a non-signifi-
cant decrement in DFS and OS among those with the
unfavorable profile compared to those with intermediate
profiles. A previous study by Petros et al also examined a
large panel of DME variants, including both phase I and
phase II enzymes, as well as drug levels, in 85 metastatic
and inflammatory breast cancer patients treated with
high-dose cyclophosphamide, cisplatin and carmustine
[7], and similarly found that patients with a CYP3A4*1B
or CYP3A5*1 variant alleles had higher parent cyclophos-
phamide levels and significantly worse OS compared to
those without the variant (P = 0.043), while those with the
GSTM1null genotype did significantly better (P = 0.041).
These data contrast with recent results of a pharmacoki-
netic study that found no effect of CYP3A4*1B variants
on formation of 4-hydroxycyclophosphamide [16]. How-Gor et al. Breast Cancer Research 2010, 12:R26
http://breast-cancer-research.com/content/12/3/R26
Page 7 of 10
ever, this study of 124 subjects had only three individuals
who carried a CYP3A4*1B variant and was thus under-
powered to examine this association. Ambrosone and
colleagues evaluated the role of GSTM1- and GSTT1-
null genotypes on disease-free and overall survival among
251 women who received treatment for incident, primary
breast cancer. Adjusting for age, race, and stage at diagno-
sis, women with null genotypes for GSTM1 and GSTT1
had reduced hazard of death (HR 0.59; 95% CI 0.36 to
0.97; and HR 0.51, 95% CI 0.29 to 0.90, respectively) in
relation to those with alleles present. Furthermore,
women who were null for both GSTM1 and GSTT1 had
one-third the hazard of death of those with alleles for
both genes present (adjusted HR, 0.28; 95% CI, 0.11 to
0.70) [17]. Sweeney et al. found that women homozygous
for genotypes associated with lower activity of
GSTP1Val105 or GSTA1*B had better overall survival
[18]. A two-SNP haplotype based on CYP3A4*1B and
CYP3A5*1A has been associated with docetaxel elimina-
tion [19], but as our subjects were not exposed to doc-
etaxel, we were not able to test the association between
this haplotype and clinical outcomes.
It is important to note that while this study utilized a
cohort of patients enrolled in a multicenter, high-dose
therapy trial, our primary study question was not related
to high-dose therapy. Our models adjusted for dose to
more closely approximate the risk estimates associated
with standard-dose therapy. However, we were also able
to examine the question of whether higher doses of cyclo-
phosphamide resulted in survival differences by polymor-
phism. The significantly worse DFS of GST-theta null
homozygotes compared to non-null individuals in the
CAF arm was not seen in the CAF+HDC arm, in which
the two groups have similar DFS. This finding is consis-
Table 3: Unadjusted models for DFS and OS1
Gene/Clinical Comparison Unadjusted DFS Unadjusted OS
HR (95% CI) Wald P-value HR (95% CI) Wald P-value
CYP2B6 Any variant vs. All WT 1.10 (0.83, 1.46) 0.51 1.12 (0.83, 1.52) 0.46
CYP2C9 Any variant vs. All WT 0.97 (0.72, 1.29) 0.82 1.01 (0.75, 1.37) 0.94
CYP2D6 G/A vs. A/A 1.07 (0.57, 2.03) 0.83 1.30 (0.64, 2.62) 0.46
G/G vs. A/A 0.89 (0.48, 1.65) 0.72 1.01 (0.51, 1.99) 0.98
CYP3A4 *1B/*1A vs. *1A/*1A 1.70 (1.10, 2.63) 0.02 1.21 (0.74, 1.96) 0.45
*1B/*1B vs *1A/*1A 1.96 (0.96, 3.98) 0.07 1.64 (0.77, 3.50) 0.20
CYP3A5 *3/*1 vs. *1/*1 0.76 (0.36, 1.59) 0.47 1.18 (0.49, 2.84) 0.72
*3/*3 vs. *1/*1 0.74 (0.38, 1.45) 0.38 1.18 (0.52, 2.67) 0.69
CYP3A5 *6/*1 vs. *1/*1 2.71 (1.01, 7.32) 0.05 2.47 (0.92, 6.66) 0.07
GSTM1 Null vs. Non-null 0.71 (0.54, 0.93) 0.02 0.71 (0.53, 0.94) 0.02
GSTT1 Null vs. Non-null 1.41 (1.00, 1.97) 0.05 1.31 (0.91, 1.88) 0.14
GSTP1 Any Var vs. All WT 1.03 (0.79, 1.36) 0.81 1.18 (0.88, 1.57) 0.27
CYP-GST 
genotype 
groups
Unfavorable vs. 
Intermediate or 
Favorable
1.29 (0.97-1.72) 0.08 1.32 (0.98-1.79) 0.07
Lymph node Continuous 1.02 (1.00, 1.04) 0.06 1.02 (1.00, 1.04) 0.10
Tumor size Continuous 1.00 (1.00, 1.01) 0.36 1.00 (1.00, 1.01) 0.13
Age Continuous 0.99 (0.97, 1.00) 0.10 0.99 (0.97, 1.01) 0.28
ER Pos vs. Neg 0.79 (0.60, 1.04) 0.10 0.78 (0.58, 1.04) 0.10
PR Pos vs. Neg 0.82 (0.62, 1.07) 0.15 0.88 (0.66, 1.17) 0.37
Race Black vs. White 1.44 (0.84, 2.48) 0.19 1.41 (0.80, 2.49) 0.23
Other vs. White 1.49 (0.83, 2.68) 0.18 1.20 (0.64, 2.28) 0.57
Arm CAF+HDC vs. CAF 0.79 (0.60, 1.03) 0.08 0.93 (0.70, 1.23) 0.59
1Cox Regression
CAF: cyclophosphamide, doxorubicin, fluorouracil; DFS: disease free survival; ER: estrogen receptor; HDC: high dose chemotherapy; HR: 
hazard ratio; PR: progesterone receptor; OS: overall survivalGor et al. Breast Cancer Research 2010, 12:R26
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tent with our biological hypothesis that higher levels of
circulating active drug are associated with improved sur-
vival, as suggested by Ambrosone et al. [8] and suggests
that high-dose chemotherapy was able to surpass some
threshold effect for this enzyme, thereby improving dis-
ease-free survival for GSTT1 null homozygotes. While it
is alternatively possible that homozygous null individuals
were less able to detoxify carcinogens and therefore had
biologically different breast cancers, as described for
other cancers [20,21], the genotypic frequencies in our
cohort were not significantly different when compared
with the general population, making this explanation
unlikely.
Several limitations in this study should be noted.
Though only 65% of the patients from INT-0121 had bio-
specimens available, the genotyped cohort did not differ
significantly from the non-genotyped cohort on any clini-
cal variable, with the exception of treatment arm. This
imbalance should not impact our results, since effective-
ness of treatment arm was not our focus and in the full
study cohort, outcome did not differ by treatment arm.
We could not assess the effect of population stratification
in our cohort because of the paucity of non-Caucasian
individuals, limiting sample sizes within strata. However,
an analysis restricted to Caucasian individuals did not
differ dramatically from the model adjusting for race;
therefore, we presented the latter model. In the parsimo-
nious prognostic model, the race variable was not signifi-
cant. Polymorphisms that could affect metabolism of
fluorouracil and doxorubicin might also influence out-
comes in this cohort. Thiotepa (a CYP2B6 inducer) did
not appear to play a role in the differential effects seen.
There was no significant effect of CYP2B6 genotype seen
in patients on the standard arm (CAF alone), in the
absence of thiotepa, which would have been expected if
the thiotepa was ameliorating a true effect of genotype.
Furthermore, CYP2D6*4, which was included to account
for the possible differential effect of variable tamoxifen
metabolism on outcome among patients whose tumors
were estrogen-receptor positive, was included in all the
Table 4: Multivariable cox regression model for DFS
Gene/Clinical Comparison Adjusted DFS
HR (95% CI) Wald P-value
CYP2B6 Any variant vs. All WT 1.06 (0.77, 1.46) 0.72
CYP2C9 Any variant vs. All WT 1.11 (0.80, 1.53) 0.53
CYP2D6 G/A vs. A/A 0.94 (0.46, 1.94) 0.87
G/G vs. A/A 0.99 (0.50, 1.99) 0.99
CYP3A4 *1B/*1A vs. *1A/*1A 2.79 (1.52, 5.14) 0.001
*1B/*1B vs *1A/*1A 2.67 (0.86, 8.34) 0.09
CYP3A5 *3/*1 vs. *1/*1 1.18 (0.47, 2.98) 0.72
*3/*3 vs. *1/*1 2.09 (0.79, 5.50) 0.14
CYP3A5 *6/*1 vs. *1/*1 1.37 (0.39, 4.79) 0.62
GSTM1 Null vs. Non-null 0.78 (0.57, 1.06) 0.12
GSTT1 Null vs. Non-null 1.32 (0.86, 2.01) 0.21
GSTP1 Any Var vs. All WT 0.94 (0.69, 1.28) 0.69
Lymph node Continuous 1.02 (1.00, 1.04) 0.03
Tumor size Continuous 1.00 (0.97, 1.01) 0.46
Age Continuous 0.99 (0.97, 1.01) 0.46
ER Pos vs. Neg -- --
PR Pos vs. Neg 1.01 (0.69, 1.50) 0.95
Race Black vs. White 1.08 (0.52, 2.25) 0.84
Other vs. White 1.84 (0.91, 3.70) 0.09
Arm CAF+HDC vs. CAF 0.66 (0.48, 0.91) 0.01
CAF: cyclophosphamide, doxorubicin, fluorouracil; DFS: disease free survival; ER: estrogen receptor; HDC: high dose chemotherapy; HR: 
hazard ratio; PR: progesterone receptorGor et al. Breast Cancer Research 2010, 12:R26
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models tested, and there was no independent effect of
this genotype, nor did it appear to confound the main
effects. We chose to limit our candidate gene pool to
m inim ize  t he  ris k of  fa lse -posi ti ve  r es ul ts.  In t o ta l,  we
tested 10 SNPs/genotype combinations. We have not
adjusted for multiple comparisons, since our relatively
large sample size and event rate provide sufficient statisti-
cal power for the number of comparisons we made. In
genome wide association studies, Bonferroni correction
i s  u n d e r t a k e n  t o  m i n i m i z e  f a l s e - p o s i t i v e s ,  b u t  t h i s
approach may be an overcorrection in our study where
the number of tested exposures is small. We did not
include SNPs associated with variable fluorouracil
metabolism, as these do not appear to be in linkage dis-
equilibrium with the variants we examined, minimizing
unmeasured confounding. Finally, this study would have
been strengthened by correlation with serum drug
metabolite levels. Unfortunately, samples were not col-
lected prospectively for this purpose, underscoring the
need for all trials to include biospecimen collection for
pharmacogenetic studies. Similarly, studies such as this
one suffer from the lack of information collected on con-
comitant medications. While several medications may
induce CYP activity, potentially modifying the expected
effect of genotype, one would anticipate that such effects
would be relevant only if a large proportion of the study
subjects were taking such medications during chemo-
therapy.
Conclusions
In conclusion, this study demonstrates that among
women receiving adjuvant chemotherapy for breast can-
cer, a polymorphism in the cyclophosphamide-metabo-
lizing enzyme CYP3A4 independently contributes to
outcomes from cyclophosphamide-based adjuvant breast
cancer chemotherapy. Taken together with previous
study findings, these results justify prospective studies to
further evaluate the relationship between genetic varia-
tion, metabolite levels and outcome to determine if tai-
lored pharmacogenetic dosing regimens can improve the
efficacy of this therapy.
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